Is Olema Pharmaceuticals struggling financially?

Yes, by its own account. Olema Pharmaceuticals told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector: Biotech/Pharma
Market cap: $935.3M
Source filing: 10-Q 12 May 2026
Balance sheet: 30 Jun 2026

Cash runway

1month

If the burn speeds up

Empty by Jul 2026
3months

If it eases off

Empty by Sep 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$48.6M

Cash burned over the last 12 months

$284.8M

What Olema Pharmaceuticals told the SEC

…approval is granted for palazestrant or OP-3136. Regulatory approval is not guaranteed and may never be obtained. As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term. We have never generated revenue from product sales and may never be profitable. Our ability to generate revenue from product sales and achieve profitability depends…

OLEMA PHARMACEUTICALS, INC., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

21.3% share-count increase The company issued stock. Each share now owns 17.5% less of the business than a year ago, before any change in the price.
Cash burn is increasing It is spending 28% more cash per year than it was, so the runway above shortens even if nothing else changes.

Cash runway

The runway math

What Olema Pharmaceuticals told the SEC

What this means

What else the numbers show

Other Biotech/Pharma companies that filed the doubt